Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3739-3744

  Martoni, Andrea A ^a   Bernardi, Alessandra ^a   Quercia, Sara ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Breast cancer; Leuprolide; Liver failure; Premenopausal patient; Tamoxifen; Trastuzumab

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LEUPRORELIN; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CASE REPORT; DRUG MIXTURE; DRUG TOLERANCE; FEMALE; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; JAUNDICE; LIVER FAILURE; LIVER FUNCTION; LIVER METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; LIVER FAILURE; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 33750694939     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL and Fraschini G: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5: 773-782, 1987.
2. Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P and Piccart MJ: EORTC Breast Cancer and Early Clinical Studies Groups: Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 39: 2439-2449, 2003.
3. Selzner M, Morse MA, Vredenburgh JJ, Meyers WC and Clavien PA: Liver metastases from breast cancer: long-term survival after curative resection. Surgery 127: 383-389, 2000.
4. Iannitti DA and Dupuy DE: Minimally invasive management of hepatic metastases. Semin Laparosc Surg 7: 118-128, 2000.
5. Gentile AL, Melotti B, Losinno F and Martoni A: Metastatic breast cancer confined to the liver: role of 5-FU/FA locoregional chemotherapy in selected pretreated patients. Ann Oncol 13: 10 (suppl. 3) (abstr.), 2002.
6. Mano MS, Cassidy J and Canney P: Liver metastases from breast cancer: management of patients with significant liver dysfunction. Cancer Treatment Rev 31: 35-48, 2005.
7. Twelves CJ, O'Reilly SM, Coleman RE, Richards MA and Rubens RD: Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer 60: 938-941, 1989.
8. O'Reilly SM, Coleman RE and Rubens RD: Phase II study of mitoxantrone for liver metastases from breast cancer. Cancer Chemother Pharmacol 25: 73-74, 1989.
9. Sharma RA, Decatris MP, Santhanam S, Roy R, Osman AE, Clarke CB, Khanna S and O'Byrne KJ: Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. Cancer Chemother Pharmacol 52: 367-370, 2003.
10. Schull B, Sheithauer W and Kornek GV: Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. Onkologie 26: 578-80, 2003.
11. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002.
12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
13. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
14. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K and Extra JM: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274, 2005.
15. Bell R, Verma S, Untch M, Cameron D and Smith I: Maximizing clinical benefit with trastuzumab. Sem Oncol 37: 35-44, 2004.
16. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H and Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95: 142-153, 2003.
17. Mass R: The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 27: 46-52, 2000.
18. De Laurentis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR and De Placido S: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11: 4741-4748, 2005.
19. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER-2/neu cross-talk in ER/HER-2-positive breast cancer. J Natl Cancer Inst 96: 926-935, 2004.
20. Osborne KC and Schiff R: Estrogen-receptor biology: continuing progress and therapeutical implications. J Clin Oncol 23: 1616-1622, 2005.
21. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E and Borgs M: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 19: 3808-3816, 2001.
22. Smith I and Dowsett M: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmeopausal women: The IMPACT trial. Breast Cancer Res Treat 82: S6, (abstr 1), 2003.
23. Zhu L, Chow LW, Loo WT, Guan XY and Toi M: HER-2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 10: 4639-4644, 2004.
24. Love RR, Due NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL and Allred DC: HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21: 453-457, 2003.
25. Argiris A, Wang CX, Whalen SG and DiGiovanna MP: Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 10: 1409-1420, 2004.
26. Ropero S, Menendez JA and Vaquez-Martin A: Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 86: 125-137, 2004.
27. Wong ZW, Marcom PK, Isaacs C et al: A phase II trial of letrozole and trastuzumab (Herceptin) for ER and/or PgR and Her2-positive metastatic breast cancer. Breast Cancer Res Treat 82: S106, (suppl. 1), (abstr. 444), 2003.